Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
4 "Seung Hwan Lee"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Genitourinary cancer
Oncological Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide with versus without Confirmatory Bone Scan
Chang Wook Jeong, Jang Hee Han, Dong Deuk Kwon, Jae Young Joung, Choung-Soo Kim, Hanjong Ahn, Jun Hyuk Hong, Tae-Hwan Kim, Byung Ha Chung, Seong Soo Jeon, Minyong Kang, Sung Kyu Hong, Tae Young Jung, Sung Woo Park, Seok Joong Yun, Ji Yeol Lee, Seung Hwan Lee, Seok Ho Kang, Cheol Kwak
Cancer Res Treat. 2024;56(2):634-641.   Published online December 5, 2023
DOI: https://doi.org/10.4143/crt.2023.848
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
In men with metastatic castration-resistant prostate cancer (mCRPC), new bone lesions are sometimes not properly categorized through a confirmatory bone scan, and clinical significance of the test itself remains unclear. This study aimed to demonstrate the performance rate of confirmatory bone scans in a real-world setting and their prognostic impact in enzalutamide-treated mCRPC.
Materials and Methods
Patients who received oral enzalutamide for mCRPC during 2014-2017 at 14 tertiary centers in Korea were included. Patients lacking imaging assessment data or insufficient drug exposure were excluded. The primary outcome was overall survival (OS). Secondary outcomes included performance rate of confirmatory bone scans in a real-world setting. Kaplan-Meier analysis and multivariate Cox regression analysis were performed.
Results
Overall, 520 patients with mCRPC were enrolled (240 [26.2%] chemotherapy-naïve and 280 [53.2%] after chemotherapy). Among 352 responders, 92 patients (26.1%) showed new bone lesions in their early bone scan. Confirmatory bone scan was performed in 41 patients (44.6%), and it was associated with prolonged OS in the entire population (median, 30.9 vs. 19.7 months; p < 0.001), as well as in the chemotherapy-naïve (median, 47.2 vs. 20.5 months; p=0.011) and post-chemotherapy sub-groups (median, 25.5 vs. 18.0 months; p=0.006). Multivariate Cox regression showed that confirmatory bone scan performance was an independent prognostic factor for OS (hazard ratio 0.35, 95% confidence interval, 0.18 to 0.69; p=0.002).
Conclusion
Confirmatory bone scan performance was associated with prolonged OS. Thus, the premature discontinuation of enzalutamide without confirmatory bone scans should be discouraged.

Citations

Citations to this article as recorded by  
  • ECM-mimicking hydrogel models of human adipose tissue identify deregulated lipid metabolism in the prostate cancer-adipocyte crosstalk under antiandrogen therapy
    Agathe Bessot, Joan Röhl, Maria Emmerich, Anton Klotz, Akhilandeshwari Ravichandran, Christoph Meinert, David Waugh, Jacqui McGovern, Jenni Gunter, Nathalie Bock
    Materials Today Bio.2025; 30: 101424.     CrossRef
  • 3,422 View
  • 134 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Cancer-Specific Mortality Among Korean Men with Localized or Locally Advanced Prostate Cancer Treated with Radical Prostatectomy Versus Radiotherapy: A Multi-Center Study Using Propensity Scoring and Competing Risk Regression Analyses
Kyo Chul Koo, Jin Seon Cho, Woo Jin Bang, Seung Hwan Lee, Sung Yong Cho, Sun Il Kim, Se Joong Kim, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung
Cancer Res Treat. 2018;50(1):129-137.   Published online March 8, 2017
DOI: https://doi.org/10.4143/crt.2017.004
AbstractAbstract PDFPubReaderePub
Purpose
Studies comparing radical prostatectomy (RP) outcomes with those of radiotherapy with or without androgen deprivation therapy (RT±ADT) for prostate cancer (PCa) have yielded conflicting results. Therefore, we used propensity score-matched analysis and competing risk regression analysis to compare cancer-specific mortality (CSM) and other-cause mortality (OCM) between these two treatments.
Materials and Methods
The multi-center, Severance Urological Oncology Group registry was utilized to identify 3,028 patients with clinically localized or locally advanced PCa treated by RP (n=2,521) or RT±ADT (n=507) between 2000 and 2016. RT±ADT cases (n=339) were matched with an equal number of RP cases by propensity scoring based on age, preoperative prostate-specific antigen, clinical tumor stage, biopsy Gleason score, and Charlson Comorbidity Index (CCI). CSM and OCM were co-primary endpoints.
Results
Median follow-up was 65.0 months. Five-year overall survival rates for patients treated with RP and RT±ADT were 94.7% and 92.0%, respectively (p=0.105). Cumulative incidence estimates revealed comparable CSM rates following both treatments within all National Comprehensive Cancer Network risk groups. Gleason score ≥ 8 was associated with higher risk of CSM (p=0.009). OCM rates were comparable between both groups in the low- and intermediate-risk categories (p=0.354 and p=0.643, respectively). For high-risk patients, RT±ADT resulted in higher OCM rates than RP (p=0.011). Predictors of OCM were age ≥ 75 years (p=0.002) and CCI ≥ 2 (p < 0.001).
Conclusion
RP and RT±ADT provide comparable CSM outcomes in patients with localized or locally advanced PCa. The risk of OCM may be higher for older high-risk patients with significant comorbidities.

Citations

Citations to this article as recorded by  
  • External beam radiation therapy versus radical prostatectomy for high-risk prostate cancer: protocol of the RECOVER study
    Caroline M. van der Starre, Chris H. Bangma, Maarten J. Bijlsma, Alfons C.M. van den Bergh, Lambertus A.L.M. Kiemeney, Wietske Kievit, Kees Vos, Diederik M. Somford, Sally M. Wildeman, Katja K.H. Aben, Igle J. de Jong, Floris J. Pos, Berdine L. Heesterman
    BMC Cancer.2025;[Epub]     CrossRef
  • Japanese clinical practice guidelines for prostate cancer 2023
    Yasuo Kohjimoto, Hiroji Uemura, Masahiro Yoshida, Shiro Hinotsu, Satoru Takahashi, Tsutomu Takeuchi, Kazuhiro Suzuki, Hiroshi Shinmoto, Tsutomu Tamada, Takahiro Inoue, Mikio Sugimoto, Atsushi Takenaka, Tomonori Habuchi, Hitoshi Ishikawa, Takashi Mizowaki,
    International Journal of Urology.2024; 31(11): 1180.     CrossRef
  • Radical prostatectomy versus external beam radiotherapy with androgen deprivation therapy for high-risk prostate cancer: a systematic review
    Berdine L. Heesterman, Katja K. H. Aben, Igle Jan de Jong, Floris J. Pos, Olga L. van der Hel
    BMC Cancer.2023;[Epub]     CrossRef
  • Risk factors for prostate-specific antigen persistence in pT3aN0 prostate cancer after robot-assisted laparoscopic radical prostatectomy: a retrospective study
    Jun Seop Kim, Jae Hoon Chung, Wan Song, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Change Jeong, Seong Il Seo, Hyun Moo Lee, Seong Soo Jeon
    Journal of Yeungnam Medical Science.2023; 40(4): 412.     CrossRef
  • Comparison of contrast-enhanced ultrasound targeted biopsies versus standard systematic biopsies for prostate cancer correction in different PSA value groups in rural China
    Dian Yuan Lu, Lan Liu, Li Shen, Jian Rong Cai, Li Xu, Li Hua Xiang
    Clinical Hemorheology and Microcirculation.2021; 77(3): 295.     CrossRef
  • Comparison of Radical Prostatectomy Versus Radiation and Androgen Deprivation Therapy Strategies as Primary Treatment for High-risk Localized Prostate Cancer: A Systematic Review and Meta-analysis
    Benjamin A. Greenberger, Nicholas G. Zaorsky, Robert B. Den
    European Urology Focus.2020; 6(2): 404.     CrossRef
  • Long short-term memory artificial neural network model for prediction of prostate cancer survival outcomes according to initial treatment strategy: development of an online decision-making support system
    Kyo Chul Koo, Kwang Suk Lee, Suah Kim, Choongki Min, Gyu Rang Min, Young Hwa Lee, Woong Kyu Han, Koon Ho Rha, Sung Joon Hong, Seung Choul Yang, Byung Ha Chung
    World Journal of Urology.2020; 38(10): 2469.     CrossRef
  • Comparing Radiotherapy to Prostatectomy for High-Risk Prostate Cancer
    Benjamin A. Greenberger, James M. Taylor, Victor E. Chen, Robert B. Den
    The Cancer Journal.2020; 26(1): 29.     CrossRef
  • Outcomes of treatment for localized prostate cancer in a single institution: comparison of radical prostatectomy and radiation therapy by propensity score matching analysis
    Narihiko Hayashi, Kimito Osaka, Kentaro Muraoka, Hisashi Hasumi, Kazuhide Makiyama, Keiichi Kondo, Noboru Nakaigawa, Masahiro Yao, Yuki Mukai, Madoka Sugiura, Shoko Takano, Eiko Ito, Hisashi Kaizu, Izumi Koike, Masaharu Hata, Masataka Taguri, Yasuhide Miy
    World Journal of Urology.2020; 38(10): 2477.     CrossRef
  • Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review
    Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, Giorgio Gandaglia, Nicola Fossati, Brian Kelly, Raj Pal, Erik Briers, Philip Cornford, Maria De Santis, Stefano Fanti, Silke Gillessen, Jeremy P. Grummet, Ann M. Henry, Thomas B.L. Lam, Michael Lar
    European Urology.2020; 77(5): 614.     CrossRef
  • Updated evidence on oncological outcomes of surgery versus external beam radiotherapy for localized prostate cancer
    Satoru Taguchi, Kenshiro Shiraishi, Hiroshi Fukuhara
    Japanese Journal of Clinical Oncology.2020; 50(9): 963.     CrossRef
  • Comparing effectiveness of radical prostatectomy versus external beam radiotherapy in patients with locally advanced prostate cancer
    Xianghong Zhou, Kun Jin, Shi Qiu, Di Jin, Xinyang Liao, Xiang Tu, Xiaonan Zheng, Jiakun Li, Lu Yang, Qiang Wei
    Medicine.2020; 99(34): e21642.     CrossRef
  • Robot or radiation? A qualitative study of the decision support needs of men with localised prostate cancer choosing between robotic prostatectomy and radiotherapy treatment
    Allan ‘Ben’ Smith, Orlando Rincones, Mark Sidhom, Pascal Mancuso, Karen Wong, Megan Berry, Dion Forstner, Leslie Bokey, Afaf Girgis
    Patient Education and Counseling.2019; 102(7): 1364.     CrossRef
  • Elective pelvic irradiation in prostate cancer patients with biochemical failure following radical prostatectomy: A propensity score matching analysis
    Changhoon Song, Sang Jun Byun, Young Seok Kim, Hanjong Ahn, Seok-Soo Byun, Choung-Soo Kim, Sang Eun Lee, Jae-Sung Kim, Christopher J.D. Wallis
    PLOS ONE.2019; 14(4): e0215057.     CrossRef
  • 125I low‑dose‑rate prostate brachytherapy and radical prostatectomy in patients with prostate cancer
    Zhien Zhou, Weigang Yan, Yi Zhou, Fuquan Zhang, Hanzhong Li, Zhigang Ji
    Oncology Letters.2019;[Epub]     CrossRef
  • Time to Disease Recurrence Is a Predictor of Metastasis and Mortality in Patients with High-risk Prostate Cancer Who Achieved Undetectable Prostate-specific Antigen Following Robot-assisted Radical Prostatectomy
    Do Kyung Kim, Kyo Chul Koo, Kwang Suk Lee, Yoon Soo Hah, Koon Ho Rha, Sung Joon Hong, Byung Ha Chung
    Journal of Korean Medical Science.2018;[Epub]     CrossRef
  • 9,809 View
  • 347 Download
  • 17 Web of Science
  • 16 Crossref
Close layer
Case Report
Mucoepidermoid Carcinoma in The External Auditory Canal: A Case Report
Jae Ho Chung, Seung Hwan Lee, Chul Won Park, Kyung Tae
Cancer Res Treat. 2012;44(4):275-278.   Published online December 31, 2012
DOI: https://doi.org/10.4143/crt.2012.44.4.275
AbstractAbstract PDFPubReaderePub
Mucoepidermoid carcinoma in the external auditory canal is extremely rare. Strategies used for treatment of mucoepidermoid carcinoma remain controversial. We present a case of mucoepidermoid carcinoma of the external auditory canal. The patient underwent lateral temporal bone resection and the surgical defect was obliterated with temporal muscle. He is currently disease-free, four years after surgery. Proper diagnostic measures and strategy for treatment of mucoepidermoid carcinoma are discussed.

Citations

Citations to this article as recorded by  
  • Primary mucoepidermoid carcinoma of the external auditory canal with a CRTC1::MAML2 fusion: A case report and a review of literature
    Carlo De la Sancha, Matthew Kuhar, Adele Kraft, Ahmed K. Alomari
    Journal of Cutaneous Pathology.2023; 50(11): 947.     CrossRef
  • Neoplasms of the Ear Canal
    Mallory Raymond
    Otolaryngologic Clinics of North America.2023; 56(5): 965.     CrossRef
  • Treatment and survival outcomes of ceruminous carcinomas of the external auditory canal: a SEER database analysis and literature review
    Brian Wanner, Kyle Rismiller, David R. Carr
    Archives of Dermatological Research.2022; 314(6): 583.     CrossRef
  • Treatment, Survival, and Demographics in Temporal Bone Malignancies: A Pooled Data Analysis
    Mitchell R Gore
    Cureus.2022;[Epub]     CrossRef
  • Ceruminous Neoplasms of the Ear
    Priyadharsini Nagarajan
    Head and Neck Pathology.2018; 12(3): 350.     CrossRef
  • Salivary mucoepidermoid carcinoma revisited
    Andrés Coca-Pelaz, Juan P. Rodrigo, Asterios Triantafyllou, Jennifer L. Hunt, Alessandra Rinaldo, Primož Strojan, Missak Haigentz, William M. Mendenhall, Robert P. Takes, Vincent Vander Poorten, Alfio Ferlito
    European Archives of Oto-Rhino-Laryngology.2015; 272(4): 799.     CrossRef
  • State of the art in temporal bone malignancies
    Sampath Chandra Prasad, Flavia D’Orazio, Marimar Medina, Andrea Bacciu, Mario Sanna
    Current Opinion in Otolaryngology & Head and Neck Surgery.2014; 22(2): 154.     CrossRef
  • 11,161 View
  • 58 Download
  • 7 Crossref
Close layer
Original Article
Prognostic Factor in Early Gastric Cancer
Seung Hwan Lee, Hyung Rok Kim, Dong Yi Kim, Young Jin Kim, Shin Kon Kim
J Korean Cancer Assoc. 1998;30(6):1096-1102.
AbstractAbstract PDF
PURPOSE
In advanced gastric cancer, the important prognostic factors are depth of invasion and status of lymph node metastasis, etc. In early gastric cancer, it remains controversial that depth of invasion or lymph node metastasis is corelated to the prognosis. A retrospective analysis of early gastric cancer was performed to evaluate the clinicopathologic features and to know the factors affecting the prognosis.
MATERIALS AND METHODS
From January 1981 to May 1997, we experienced 1850 cases of gastric cancer who performed gastric resections. Among them, 371 cases were early gastric cancer (20.1% of all resected gastric cancer cases). We defined 12 variable factors such as sex, age, tumor location, gross type, histologic type, depth of invasion, status of lymph node metastasis, tumor size, DNA ploidy pattem, stage, operation type, and resection type for prognostic factor and analyzed them.
RESULTS
Overall five year survival rate was 89.6% and ten year survival rate was 82.0%. The trend of annual incidence in recent nine years showed steady increase from 13.1% in 1988 to 25.7% in 1996. Survival showed no significant correlation with sex, age, tumor location, gross type, histologic type, tumor size, DNA ploidy, resection type. According to univariate analysis, depth of invasion, lymph node metastasis, stage had statistically significant association with prognosis. Among them, lymph node metastasis had an inde- pendent and predominant impact on survival according to multivariate analysis.
CONCLUSION
Early gastric cancer appears to show steady increase of annual incidence, and lymph node metastasis appears to be closely related to the prognosis.
  • 3,193 View
  • 27 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP